Emergent BioSolutions Inc. reached a $40 million class action settlement to settle allegations that it misled investors about its ability to manufacture Covid-19 vaccines.
The lawsuit, filed in the US District Court for the District of Maryland, claimed that Emergent wasn’t earnest about the capabilities of its Bayview facility in Baltimore when it reached $1.5 billion worth of deals with the federal government, Johnson & Johnson, and AstraZeneca Plc to manufacture Covid-19 vaccines. The company’s stock initially soared after those deals, but tanked after repeated contamination incidents and the loss of its federal contract.
The settlement “is nearly three times ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.